| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787815 | Journal of Thoracic Oncology | 2018 | 12 Pages |
Abstract
In conclusion, there was no significant efficacy signal, and dasatinib monotherapy will not continue to be studied in MPM. However, our study demonstrated that PDGFR subtypes (platelet-derived growth factor receptor alpha and PDGFRB) may have differential roles in prognosis and resistance to antiangiogenic tyrosine kinase inhibitors and are important potential therapeutic targets that require further investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Anne S. MD, Heather Lin, Brett W. MD, J. Jack PhD, David MD, Ara MD, Steven MD, Reza MD, John MD, PhD, Monique PhD, Youhong Fan, Maria Nunez, Lixia Diao, Jing PhD, Junya PhD, Ignacio I. MD, Waun Ki MD,